As of December of 2021, Dillon Capital has made a strategic shift which is that this point forward, Dillon Capital will spend 100% of its time working exclusively with companies in the health, wellness, and longevity sectors, including both mental and physical health. This includes but is not limited to companies which are involved in healthcare (excluding pharma), precision medicine as applied to medtech and medical devices, genomics, production of organic plant-based foods, water purification, , the herb and spice businesses, biotech (including research-backed medicinal benefits of psilocybin and marijuana), and cosmetics and beauty products. Since 1998, Dillon has helped companies grow exponentially by bringing in its value-added and strategic relationships that have been developed over forty years in business. Dillon and the hedge funds run by Flink have worked with the management teams and boards (both corporate and advisory) of hundreds of small cap public and private companies. Through these hedge funds founded by Flink as well as Dillon, Flink has overseen private placement investments in over five hundred companies during a twenty-year period with capital deployed greater than $850 million. Approximately 90% of these investments were private placements in micro and small cap public companies, whereas the other 10% was in private companies. Dillon, as a consulting and advisory firm, operates under the philosophy of having ‘skin in the game’. Meaning, it invests its own capital in most companies it works with, both public and private. It seeks out great entrepreneurs, founders, a twenty-year period with capital deployed greater than $850 million. Dillon, as a consulting and advisory firm, operates under the philosophy of having ‘skin in the game’. Meaning, it invests its own capital in most companies it works with, both public and private. It seeks out great entrepreneurs, founders, and CEO’s who have a track record in business. Call (847) 650-7782